{"title":"[Interpretation of the Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)].","authors":"Y M Mao","doi":"10.3760/cma.j.cn501113-20230829-00077","DOIUrl":null,"url":null,"abstract":"<p><p>Drug can cause almost all known types of acute, subacute, and chronic liver injuries. Drug-induced liver injury (DILI) is an important cause of unexplained liver injury in clinical practice. Correct diagnosis of DILI is challenging due to lack of specific diagnostic biomarkers, especially in patients with pre-existing liver disease and multiple concomitant drugs. A comprehensive understanding of the risk factors, clinical features, and prognosis of liver injury caused by different drugs will help physicians to recognize, diagnose, and manage it timely. Although the guideline was developed based on evidence-based medicine provided by the latest studies, there is limited high-quality evidence in the field of DILI. Therefore, this guideline should be interpreted with caution, and physicians should adopt an optimal diagnostic and therapeutic strategy for individual patients within the framework of the guideline.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 4","pages":"312-317"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20230829-00077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Drug can cause almost all known types of acute, subacute, and chronic liver injuries. Drug-induced liver injury (DILI) is an important cause of unexplained liver injury in clinical practice. Correct diagnosis of DILI is challenging due to lack of specific diagnostic biomarkers, especially in patients with pre-existing liver disease and multiple concomitant drugs. A comprehensive understanding of the risk factors, clinical features, and prognosis of liver injury caused by different drugs will help physicians to recognize, diagnose, and manage it timely. Although the guideline was developed based on evidence-based medicine provided by the latest studies, there is limited high-quality evidence in the field of DILI. Therefore, this guideline should be interpreted with caution, and physicians should adopt an optimal diagnostic and therapeutic strategy for individual patients within the framework of the guideline.
药物可导致几乎所有已知类型的急性、亚急性和慢性肝损伤。在临床实践中,药物性肝损伤(DILI)是不明原因肝损伤的一个重要原因。由于缺乏特异性诊断生物标志物,正确诊断药物性肝损伤具有挑战性,尤其是对已存在肝病和同时服用多种药物的患者。全面了解不同药物导致肝损伤的风险因素、临床特征和预后有助于医生及时识别、诊断和处理肝损伤。虽然本指南是根据最新研究提供的循证医学证据制定的,但在 DILI 领域的高质量证据有限。因此,应谨慎解释本指南,医生应在指南框架内针对不同患者采取最佳诊断和治疗策略。